MA43291A1 - Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2, and their use - Google Patents

Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2, and their use

Info

Publication number
MA43291A1
MA43291A1 MA43291A MA43291A MA43291A1 MA 43291 A1 MA43291 A1 MA 43291A1 MA 43291 A MA43291 A MA 43291A MA 43291 A MA43291 A MA 43291A MA 43291 A1 MA43291 A1 MA 43291A1
Authority
MA
Morocco
Prior art keywords
combinations
positive allosteric
glutamatergic receptor
receptor subtype
allosteric modulators
Prior art date
Application number
MA43291A
Other languages
French (fr)
Other versions
MA43291B1 (en
Inventor
Brian D Klein
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Priority claimed from PCT/EP2015/051029 external-priority patent/WO2015110435A1/en
Publication of MA43291A1 publication Critical patent/MA43291A1/en
Publication of MA43291B1 publication Critical patent/MA43291B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des combinaisons comprenant un modulateur allostérique positif (« pam ») de sous-type 2 de récepteur glutamatergique métabotrope (« mglur2 ») ou un sel ou solvate pharmaceutiquement acceptable de ce dernier, ou un agoniste orthostérique de composé de sous-type 2 de récepteur glutamatergique métabotrope ou un sel ou solvate pharmaceutiquement acceptable de ce dernier, et un ligand de protéine 2a de vésicule synaptique (« sv2a »).The present invention relates to combinations comprising a methotrotropic glutamatergic receptor subtype 2 ("mglur2") positive allosteric modulator ("pam"), or a pharmaceutically acceptable salt or solvate thereof, or an orthosteric subtype compound agonist. type 2 metabotropic glutamatergic receptor or a pharmaceutically acceptable salt or solvate thereof, and a synaptic vesicle protein 2a ligand ("sv2a").

MA43291A 2014-02-04 2015-01-20 Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2, and their use MA43291B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14153880 2014-02-04
PCT/EP2015/051029 WO2015110435A1 (en) 2014-01-21 2015-01-20 Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use

Publications (2)

Publication Number Publication Date
MA43291A1 true MA43291A1 (en) 2018-11-30
MA43291B1 MA43291B1 (en) 2019-05-31

Family

ID=50030211

Family Applications (3)

Application Number Title Priority Date Filing Date
MA43291A MA43291B1 (en) 2014-02-04 2015-01-20 Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2, and their use
MA39209A MA39209A1 (en) 2014-02-04 2015-01-20 Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2, and their use
MA43290A MA43290B1 (en) 2014-02-04 2015-01-20 Combinations comprising positive allosteric modulators or orthosteric agonists of subtype 2 metabotropic glutamatergic receptor, and their use

Family Applications After (2)

Application Number Title Priority Date Filing Date
MA39209A MA39209A1 (en) 2014-02-04 2015-01-20 Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2, and their use
MA43290A MA43290B1 (en) 2014-02-04 2015-01-20 Combinations comprising positive allosteric modulators or orthosteric agonists of subtype 2 metabotropic glutamatergic receptor, and their use

Country Status (1)

Country Link
MA (3) MA43291B1 (en)

Also Published As

Publication number Publication date
MA43290B1 (en) 2019-05-31
MA43291B1 (en) 2019-05-31
MA43290A1 (en) 2018-11-30
MA39209A1 (en) 2017-10-31

Similar Documents

Publication Publication Date Title
EA201892119A1 (en) DRUGS, OBTAINED BY COMBINING AGONIST FXR AND ARB
MA41481B1 (en) Dosage regimen for ponesimod, a selective s1p1 receptor agonist
CA2916222C (en) Stable liquid formulation of amg 416 (etelcalcetide)
EA201692433A1 (en) PPAR COMPOUNDS FOR THE USE IN THE TREATMENT OF FIBROZAL DISEASES
EA201790373A1 (en) METHODS OF OBTAINING MODULATORS OF TOLL-SIMILAR RECEPTORS
CY1124207T1 (en) COMBINATIONS COMPRISING POSITIVE ALLOSTERIC REGULATORS OF GLUTAMINERGIC RECEPTOR SUBTYPE 2 AND USES THEREOF
MA43291A1 (en) Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2, and their use
PH12019500128A1 (en) Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
EA201991895A3 (en) COMBINATIONS CONTAINING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR 2 SUBTYPE, AND THEIR APPLICATION
GB201816746D0 (en) Cyclic apelin receptor agonists
GB201805675D0 (en) Compounds For Use As Apelin Receptor Antagonists
GB201914756D0 (en) Cyclic apelin receptor agonists
PT3431106T (en) Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use